NCT02196324View on ClinicalTrials.gov

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

July 9, 2014

Primary Completion Date

May 27, 2016

Study Completion Date

June 10, 2016

Conditions
Prurigo Nodularis
Interventions
DRUG

serlopitant

NK1 receptor antagonist

DRUG

Placebo

Placebo

Trial Locations (15)

10117

Study Site 07, Mitte

20246

Study Site 09, Hamburg

23538

Study Site 04, Lübeck

24105

Study Site 03, Kiel

40225

Study Site 12, Düsseldorf

48149

Study Site 01, Münster

53127

Study Site 08, Bonn

55101

Study Site 14, Mainz

56242

Study Site 15, Selters

60590

Study Site 02, Frankfurt

69120

Study Site 05, Heidelberg

72076

Study Site 10, Tübingen

80337

Study Site 16, München

01307

Study Site 06, Dresden

04103

Study Site 11, Leipzig

All Listed Sponsors
lead

Vyne Therapeutics Inc.

INDUSTRY

NCT02196324 - A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) | Biotech Hunter | Biotech Hunter